

This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the administration or supply of

Fusidic Acid 2% Cream and Sodium Fusidate 2% Ointment

By registered health care professionals for

Acute Impetigo caused by Staphylococcal Skin Infections

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

PGD NUMBER 91

1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021

2. Medicines practice guideline 2: *Patient group directions*

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care [PGD website FAQs](#)

3. PGD development

Refer to the [NICE PGD competency framework for people developing PGDs](#)

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

4. PGD authorisation

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

5. PGD adoption by the provider

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job title and organisation	Signature	Date	Applicable or not applicable to area

6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the [NICE PGD competency framework for health professionals using PGDs](#)

	Requirements of registered Healthcare professionals working under the PGD
Qualifications and professional registration	<ul style="list-style-type: none"> Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy Pharmacists must be practising in Manx Care authorised premises i.e. contracted pharmacy premises
Initial training	<ul style="list-style-type: none"> Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD Local training in the use of PGDs
Competency assessment	Staff will be assessed on their knowledge of drugs and clinical assessment as part the competency framework for registered health professionals using PGDs
Ongoing training and competency	The registered health care professionals should make sure they are aware of any changes to the recommendations for this medication; it is the responsibility of the registered health care professionals to keep up to date with continuing professional development. PGD updates will be held every two years

7. Clinical Conditions

Clinical condition or situation to which this PGD applies	Diagnosis of impetigo with a probable cause staphylococcal skin infection
Inclusion criteria	<ul style="list-style-type: none"> • Diagnosis of impetigo with a probable cause staphylococcal skin infection • Adults and children at least one month old
Exclusion criteria	<ul style="list-style-type: none"> • Hypersensitivity to Fusidic Acid, Sodium Fusidate or any of the excipients contained in the product • Large non-localised areas of infection • Where treatment would involve application to an area of skin sensitised (inflamed) by another topical agent, dressing or bandage • Pregnancy or breast feeding
Cautions (including any relevant action to be taken)	<ul style="list-style-type: none"> • Avoid contact of cream or ointment with eyes • If the patient is receiving any concomitant medication or treatment it is the responsibility of the pharmacist to ensure that treatment with the drug detailed in this patient group direction is appropriate • If in any doubt advice should be sought and recorded before the drug is administered
Arrangements for referral for medical advice	Patient should be referred to a more experienced clinical practitioner for further assessment
Action to be taken if patient excluded	Patient should be referred to a more experienced clinical practitioner for further assessment
Action to be taken if patient declines treatment	<ul style="list-style-type: none"> • A verbal explanation should be given to the patient on: the need for the medication and any possible effects or potential risks which may occur as a result of refusing treatment • This information must be documented in the patients' health records • Any patient who declines care must have demonstrated capacity to do so • Where appropriate care should be escalated

8. Details of the medicine

Name, form and strength of medicine	Fusidic Acid 2% cream or Sodium fusidate 2% ointment
Legal category	Prescription Only Medicine (POM)
Indicate any <u>off-label use</u> (if relevant)	None
Route/method of administration	Topical to skin
Dose and frequency	Apply to the affected area(s) 3 x a day
Quantity to be administered and/or supplied	1 x tube

Maximum or minimum treatment period	For up to 7 days
Storage	Room temperature
Adverse effects	<ul style="list-style-type: none"> • Hypersensitivity reactions to Fusidic Acid in the form of skin rashes • Rarely mild stinging or irritation on application <p>Special warnings and precautions for use:</p> <ul style="list-style-type: none"> • Bacterial resistance has been reported to occur with the use of Fusidic acid/sodium fusidate. As with all antibiotics, extended or recurrent use may increase the risk of developing antibiotic resistance. To avoid the development of resistance, fusidic acid/sodium fusidate should be used for no longer than 10 days • Fusidic acid/sodium fusidate should not be used in infections caused by non-susceptible organisms, in particular, <i>Pseudomonas aeruginosa</i>. If infection with non-staphylococcal organism is suspected, referral is required. • Extended or recurrent use may increase the risk of developing contact sensitisation • When Fusidic acid 20mg/g cream or sodium fusidate 20mg/g ointment is used on the face, care should be taken to avoid the eyes, because Fusidic acid and sodium fusidate can cause irritation of the conjunctiva • Fusidic acid 20mg/g cream contains butylhydroxyanisole, cetyl alcohol and potassium sorbate which may cause local skin reactions (e.g. contact dermatitis). Butylhydroxyanisole may also cause irritation to the eyes and mucous membranes • Sodium fusidate 20mg/g ointment contains lanolin, cetyl alcohol and butylhydroxytoluene which may cause local skin reactions (e.g. contact dermatitis). Butylhydroxytoluene may also cause irritation to the eyes and mucous membranes • If necessary seek appropriate emergency advice and assistance • Document in the individual's PMR record and inform appropriate doctor/independent nurse prescriber
Records to be kept	The administration of any medication given under a PGD must be recorded within the patient's medical records

9. Patient information

<p>Verbal/Written information to be given to patient or carer</p>	<ul style="list-style-type: none"> • Verbal information must be given to patients and or carers for all medication being administered under a PGD • Where medication is being supplied under a PGD, written patient information leaflet must also be supplied • A patient information leaflet is available on request • Wash hands before and immediately after application • When Fusidic acid 20 mg/g cream/sodium fusidate 20mg/g ointment is used on the face, care should be taken to avoid the eyes, because Fusidic acid/sodium fusidate can cause irritation of the conjunctiva • Impetigo can be extremely infectious so do not share flannels/towels/pillows; these should be washed at high temperature after use • Avoid touching the spots • Encourage frequent hand washing • Avoid close contact with others. Children with impetigo should be kept from nursery, playgroup or school until the spots have dried up and are no longer leaking fluid • Keep nails cut short
<p>Follow-up advice to be given to patient or carer</p>	<p>If symptoms do not improve or worsen or you become unwell, seek medical advice immediately</p>

10. Appendix A

References
<ol style="list-style-type: none"> 1. British National Formulary (BNF) available online: https://bnf.nice.org.uk 2. Nursing and Midwifery (2018) "The code" available online: https://www.nmc.org.uk 3. Current Health Care Professions Council standards of practice 4. General Pharmaceutical Council standards 5. The General Optical Council 6. Electronic medicines compendium available online: https://www.medicines.org.uk 7. Clinical Knowledge Summaries (2016): Impetigo http://cks.nice.org.uk/impetigo 8. NHS Choices: Impetigo http://www.nhs.uk/conditions/impetigo/Pages/Introduction.aspx 9. Addison, B, Brown, A, Edwards, R, and G Gray. 2012. Minor illness or Major Disease? Pg 108-109

11. Appendix B

Health professionals agreed to practice

- Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor
- A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves